FORMULATION COMPRISING BUPRENORPHINE

Korea, Republic of Patent

APP PUB NO KR-20110005919-A
SERIAL NO

20117000035

Stats

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, C ther , of 0.2 ng/ml or greater which is maintained for a duration T maint of at least 2 hours.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IONIX PHARMACEUTICALS LTDGBBRITAIN CAMB

International Classification(s)

Inventor(s)

Inventor Name Address
CASTILE JONATHAN DAVID NOTTINGHAM NG7 2TN
WATTS PETER JAMES NOTTINGHAM NG7 2TN
BIRCH PHILLIP JOHN HERTFORDSHIRE SG12 0DP
HAYES ANN GAIL CAMBRIDGE CB4 0PA

Cited Art Landscape

Load Citation